{"id":"W4396590738","doi":"10.1158/1538-7445.sabcs23-gs01-05","title":"Abstract GS01-05: Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Chemotherapy; Oncology; Olaparib; Internal medicine; Open label; Induction chemotherapy; Cancer; Randomized controlled trial; Immunotherapy; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001770099,0.001946396,0.002215983,0.000393968,0.0003578753,0.001194187,0.00127495,0.001632639,0.01083139],"category_scores_gemma":[0.0009618267,0.0007355938,0.001859783,0.000417069,0.001002565,0.001012369,0.0005601122,0.004055938,0.001914382],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001471239,"about_ca_system_score_gemma":0.001873459,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001446875,"about_ca_topic_score_gemma":0.003065408,"domain_scores_codex":[0.9994506,0.0002976643,0.00002701203,0.0000966414,0.00004318923,0.00008483681],"domain_scores_gemma":[0.9992642,0.000124851,0.0001683071,0.00005181894,0.00003686943,0.0003538508],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9743013,0.01064081,0.0005261881,0.0003512949,0.0006293295,0.00002735884,0.00002169842,0.000283575,0.003587961,0.00007017708,0.001191061,0.008369209],"study_design_scores_gemma":[0.8912139,0.1047696,0.002185554,0.00002608756,0.000450697,0.00002705603,0.0000160493,0.0002414375,0.000374675,0.00008540228,0.0006007297,0.000008866709],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816324,0.002833043,0.0005348045,0.001164359,0.0005443362,0.005597278,0.00416389,0.0002162135,0.003313641],"genre_scores_gemma":[0.979129,0.002050876,0.001420304,0.002349199,0.0004946748,0.004861478,0.00416297,0.00003745815,0.00549407],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01083139,"threshold_uncertainty_score":0.03623462,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1435100401955755,"score_gpt":0.4841436015656345,"score_spread":0.3406335613700591,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}